The estimated Net Worth of Andre S Hoffmann is at least $10.1 million dollars as of 6 June 2020. Mr. Hoffmann owns over 6,327 units of Innovator ETFs Trust stock worth over $9,953,291 and over the last 9 years he sold INOV stock worth over $0. In addition, he makes $125,000 as Independent Director at Innovator ETFs Trust.
Sign up
Mr. Hoffmann INOV stock SEC Form 4 insiders trading
Andre has made over 2 trades of the Innovator ETFs Trust stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 6,327 units of INOV stock worth $184,179 on 6 June 2020.
The largest trade he's ever made was buying 200,000 units of Innovator ETFs Trust stock on 16 December 2016 worth over $1,858,000. On average, Andre trades about 22,925 units every 141 days since 2015. As of 6 June 2020 he still owns at least 341,920 units of Innovator ETFs Trust stock.
You can see the complete history of Mr. Hoffmann stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andre Hoffmann biography
Andre S. Hoffmann is Independent Director of the INOVALON HOLDINGS, INC. Mr. Hoffmann has served as a director of Inovalon since 2008. Since 2006, Mr. Hoffmann has served as the Vice Chairman of the Board of Roche Holding, Ltd., one of the world’s largest diversified healthcare companies focused on medical diagnostics and treatments, and has served as a board member since 1996. Mr. Hoffmann served as Non-Executive Vice Chairman of Givaudan SA, the world’s leading flavor and fragrance company, from 2008 to 2016, and as a non-executive member of the Board from 2000 to 2016. Since 1999, Mr. Hoffmann has also served as the Chairman and owner of Massellaz S.A., a research and advisory company, and, from 2005 to 2013, served as the Chairman and owner of Nemadi Advisors Ltd., a private equity advisory company. Mr. Hoffmann also serves as a director for Genentech Inc., one of the world’s largest biotechnology companies and a subsidiary of Roche, and Amazentis SA, a private therapeutics and diagnostics company. Mr. Hoffmann studied economics at the University of St. Gallen and holds a Master of Business Administration from INSEAD.
What is the salary of Andre Hoffmann?
As the Independent Director of Innovator ETFs Trust, the total compensation of Andre Hoffmann at Innovator ETFs Trust is $125,000. There are 12 executives at Innovator ETFs Trust getting paid more, with Peter De Bock having the highest compensation of $2,866,730.
How old is Andre Hoffmann?
Andre Hoffmann is 62, he's been the Independent Director of Innovator ETFs Trust since 2008. There are 6 older and 6 younger executives at Innovator ETFs Trust. The oldest executive at Innovator ETFs Trust is Denise Fletcher, 71, who is the Independent Director.
What's Andre Hoffmann's mailing address?
Andre's mailing address filed with the SEC is 4321, Collington Road, Essington, Bowie, Prince George's County, Maryland, 20716, United States.
Insiders trading at Innovator ETFs Trust
Over the last 10 years, insiders at Innovator ETFs Trust have traded over $17,222,256 worth of Innovator ETFs Trust stock and bought 1,096,675 units worth $14,934,745 . The most active insiders traders include Keith R Dunleavy, Christopher E Greiner et William D Green. On average, Innovator ETFs Trust executives and independent directors trade stock every 36 days with the average trade being worth of $987,207. The most recent stock trade was executed by William J Jr Teuber on 18 June 2021, trading 9,165 units of INOV stock currently worth $266,793.
What does Innovator ETFs Trust's logo look like?
Complete history of Mr. Hoffmann stock trades at Innovator ETFs Trust
Innovator ETFs Trust executives and stock owners
Innovator ETFs Trust executives and other stock owners filed with the SEC include:
-
Peter De Bock,
Chief Administrative Officer -
Jonathan Boldt,
Chief Financial Officer -
Jason Capitel,
Chief Operating Officer -
Robert Wychulis,
President -
Isaac Kohane,
Independent Director -
William Teuber,
Independent Director -
Lee Roberts,
Independent Director -
William Green,
Independent Director -
Denise Fletcher,
Independent Director -
Mark Pulido,
Non-Independent Director -
Dr. Keith R. Dunleavy,
Founder, Chairman & CEO -
Keith Dunleavy,
Chairman of the Board, Chief Executive Officer -
Andre Hoffmann,
Independent Director -
Dr. Paige C. Kilian M.D.,
Chief Medical Officer -
Ingrid E. Olsen,
Chief People Officer -
Kim E. Collins,
Sr. VP of Corp. Marketing & Communications -
Beverly Allen,
Gen. Counsel, Chief Compliance & Privacy Officer -
Hulus Alpay,
VP of Investor Relations -
Geoff Charron,
Chief Technology Officer -
June Duchesne,
Chief Legal Officer -
Shauna L Vernal,
Chief Legal Officer -
Joseph R Rostock,
Chief Technology Officer -
Daniel L Rizzo,
Chief Innovation Officer -
Thomas R Kloster,
Chief Financial Officer -
Christopher E Greiner,
Chief Product Officer & COO -
John Michael Burgin,
Chief Product Officer -
Eron Kelly,
President